MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Phase 2
Completed
Conditions
Disorder Related to Bone Marrow Transplantation
Lymphoma
Interventions
Drug: Fludarabine
Drug: Melphalan
Procedure: Allogeneic Transplant
Drug: Thymoglobulin
First Posted Date
2007-07-25
Last Posted Date
2020-12-29
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
33
Registration Number
NCT00506129
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

FM 140 vs FM100 Study in Patients With Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Melphalan
Drug: Fludarabine
Procedure: Stem Cell Infusion
Drug: Rituximab
First Posted Date
2007-07-25
Last Posted Date
2014-10-17
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
52
Registration Number
NCT00505895
Locations
🇺🇸

UT MD . Anderson Cancer Center, Houston, Texas, United States

Busulfan and Fludarabine in Patients With AML and MDS

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: Busulfan
Drug: Fludarabine
First Posted Date
2007-07-18
Last Posted Date
2012-05-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
200
Registration Number
NCT00502905
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Cord Blood Expansion on Mesenchymal Stem Cells

Phase 1
Completed
Conditions
Leukemia
Myelodysplastic Syndrome
Interventions
Procedure: Cord Blood Infusion
Drug: Busulfan
Drug: Fludarabine
Drug: Rituximab
Other: ATG
Drug: Cyclophosphamide
Drug: Clofarabine
Radiation: Total Body Irradiation (TBI)
Drug: Melphalan
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: G-CSF
First Posted Date
2007-07-10
Last Posted Date
2020-02-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
98
Registration Number
NCT00498316
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Phase 2
Terminated
Conditions
Sickle Cell Disease
Interventions
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Sirolimus
Procedure: Allogeneic bone marrow transplant
Radiation: Total body irradiation - 200
Drug: Levetiracetam
Biological: Anti-thymocyte globulin
Radiation: Total body irradiation - 400
First Posted Date
2007-06-21
Last Posted Date
2019-04-17
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
43
Registration Number
NCT00489281
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 4
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2007-06-20
Last Posted Date
2008-11-18
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
47
Registration Number
NCT00488709
Locations
🇪🇸

Hospital Sant Pau, Barcelona, Spain

🇪🇸

Hospital Ntra. Sra. de Sonsoles, Avila, Spain

🇪🇸

Hosptal Joan XXIII, Tarragona, Spain

and more 13 locations

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia

Phase 4
Completed
Conditions
Myelodysplastic Syndrome
Acute Myeloblastic Leukemia
First Posted Date
2007-06-18
Last Posted Date
2008-11-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
200
Registration Number
NCT00487448
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

🇪🇸

Hospital del Mar, Barcelona, Spain

and more 12 locations

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Phase 1
Terminated
Conditions
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Leukemia
Interventions
Drug: Oxaliplatin
Drug: Fludarabine
Drug: Cytarabine
First Posted Date
2007-06-01
Last Posted Date
2012-08-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT00480987
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

Not Applicable
Terminated
Conditions
Epidermolysis Bullosa
Interventions
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: hematopoietic bone marrow transplantation
First Posted Date
2007-05-24
Last Posted Date
2017-12-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
7
Registration Number
NCT00478244
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Myelofibrosis
Interventions
Drug: Busulfan
Drug: Fludarabine
Drug: Thymoglobulin (ATG)
First Posted Date
2007-05-17
Last Posted Date
2019-05-21
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
63
Registration Number
NCT00475020
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy